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The forkhead O (FoxO) family of transcription factors participates in diverse physiologic processes,
including induction of cell-cycle arrest, stress resistance, differentiation, apoptosis, andmetabolism.
Several recent studies indicate that FoxO-dependent signaling is required for long-term regenerative
potential of the hematopoietic stem cell (HSC) compartment through regulation of HSC response to
physiologic oxidative stress, quiescence, and survival. These observations link FoxO function in
mammalian systems with the evolutionarily conserved role of FoxO in promotion of stress resistance
and longevity in lower phylogenetic systems. Furthermore, these findings have implications for aging
in higher organisms and in malignant stem cell biology, and suggest that FoxOs may play an impor-
tant role in the maintenance and integrity of stem cell compartments in a broad spectrum of tissues.FoxO Family Members and HSCs
Longevity in higher-level organisms is dependent on the
maintenance of tissue homeostasis that is in part deter-
mined by the integrity of tissue-specific stem cells. There
are several adult tissue compartments in mammalian
systems that are highly reliant on stem cells for their main-
tenance and propagation, including skin, gastrointestinal
epithelium, and blood (Blanpain et al., 2004; Radtke and
Clevers, 2005; Till andMcCulloch, 1961). In addition, there
is convincing evidence for the existence of adult tissue
stem cells in the central nervous system, and cells with
properties of stem cells have been identified in lung in mu-
rine models (Kim et al., 2005; Reynolds and Weiss, 1992).
In the skin, gut, and hematopoietic systems, stem cells
persist for the life of the organism and give rise to commit-
ted progenitors that subserve various functions of termi-
nally differentiated cells. For example, in the gut, stem
cells that reside in the base of the colonic crypts give
rise to progeny that terminally differentiate into colonic ep-
ithelial cells. In the hematopoietic system, stem cells give
rise to a broad spectrum of terminally differentiated effec-
tor cells that are responsible for innate and humoral im-
mune response to infection, hemostatic homeostasis,
and oxygen delivery.
Hematopoietic development is regulated by a dynamic
balance between HSC self-renewal and differentiation to
mature effector cells. The balance between self-renewal
and differentiation is of critical importance: too little self-
renewal or too much differentiation may jeopardize the
ability to sustain hematopoiesis throughout life, whereas
excessive self-renewal and/or aberrant differentiation
may result in leukemogenesis. The regulation of HSC
self-renewal is not fully understood, but recent studies140 Cell Stem Cell 1, August 2007 ª2007 Elsevier Inc.have underscored the importance of cell cycle, apoptosis,
and oxidative stress response in HSC homeostasis.
Recent data indicate that FoxO family members play a
critical role in these physiologic processes in the HSC
compartment and thereby regulate maintenance and
integrity of HSCs.
Regulation of FoxO Transcriptional Activity
The forkhead box (Fox) family of proteins is a large family of
transcription factors with diverse physiological functions.
The evolutionary conservation of Fox proteins from yeast
to humans, and their diverse biological functions, highlight
the importance of these proteins in developmental pro-
cesses. All members of the Fox family share a conserved
110 amino acid DNA-binding domain that is referred to
as the ‘‘forkhead box’’ or ‘‘winged helix’’ domain. Over
100 forkheadgeneshavebeen identified todate, and in hu-
mans, this family of transcription factors has been subdi-
vided into19subgroups (FOXA-FOXS) basedonsequence
similarity (reviewed in Wijchers et al., 2006).
The FoxO subfamily (FoxO1, FoxO3, FoxO4, and
FoxO6) plays an important role as effectors of the PI3K/
AKT pathway in diverse cellular processes that include
induction of cell-cycle arrest, stress resistance, apoptosis,
differentiation, and metabolism (reviewed in Greer and
Brunet, 2005). FoxO1, FoxO3, and FoxO4 expression is
abundant in most tissues, including those of the hemato-
poietic system, with highest expression of the different
isoforms found in the adipose tissue, brain, and heart,
respectively. In contrast, the expression of FoxO6
appears to be restricted to the developing brain and has
a variant mechanism for regulation of its transcriptional
activity, as described below.
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tions enacted by FoxO factors, that there are multiple
levels of control of FoxO function in the cellular milieu
that include phosphorylation, acetylation, and ubiquitina-
tion (reviewed in van der Horst and Burgering, 2007).
FoxO phosphorylation can play both inhibitory and
activating roles in FoxO function. AKT inactivates
FoxO1, FoxO3, and FoxO4 by direct phosphorylation of
three conserved serine and threonine residues (Thr32,
Ser253, and Ser315 in FoxO3), creating a binding motif
for the 14-3-3 chaperone proteins that interfere with the
DNA binding domain of FoxOs and facilitate the transloca-
tion of FoxOs from the nucleus to the cytoplasm (Brunet
et al., 1999, 2002). Cytoplasmic FoxOs are targeted for
ubiquitination and proteosomal degradataion. The regula-
tion of FoxO6 activity is not well understood, in that it lacks
the C-terminal AKT phosphorylation site and is primarily
localized in the nucleus (van der Heide et al., 2005). In
addition to AKT, other kinases, such as serum and gluco-
corticoid inducible kinase (SGK), casein kinase 1 (CK1),
dual tyrosine phosphorylated regulated kinase 1
(DYRK1), and I kappa-B kinase b (IKKb) participate in
phosphorylation of specific serine residues in FoxOs and
are thought to affect subcellular localization of FoxOs in
a manner similar to AKT.
Conversely, activation of Jun N-terminal kinase (JNK) or
mammalian sterile 20-like kinase-1 (Mst1) in response to
Figure 1. PI3K/AKT and Stress Stimuli-Mediated Pathways
Regulate FoxO Function
Activation of the PI3K/AKT pathway in response to insulin or growth
factor stimulation results in recruitment and activation of the serine-
threonine kinase AKT. Activated AKT inhibits FoxO function by
phosphorylation of FoxOs at three conserved residues. The dual spec-
ificity lipid and protein phosphatase PTEN antagonizes PI3K/AKT
activity. In the presence of stress stimuli, JNK phosphorylates FoxOs
at a distinct set of threonine residues andmediates their nuclear import
and transcriptional activation of stress resistance-inducing target
genes. Similarly, presence of stress stimuli activates deacetylation of
FoxOs by SIRT1 and monoubiquitination of FoxOs by E3 ligase, which
both promote FoxO-mediated transcription of genes inducing stress
resistance.stress stimulation results in phosphorylation of FoxOs at
a distinct set of threonine residues and results in nuclear
import, rather than export, of FoxOs and subsequent tran-
scriptional activation (Essers et al., 2004; Lehtinen et al.,
2006). The effects of FoxO phosphorylation by JNK thus
appear to be counterregulatory to those mediated by
PI3K/AKT phosphorylation. However, it should be noted
that stressful stimuli override the negative regulatory ef-
fects of growth factors on FoxO activation (Brunet et al.,
2004; Wang et al., 2005), suggesting that among the
most important functions of these highly evolutionarily
conserved proteins is protection of mammalian cells
from environmental stress, similar to their role in lower
organisms.
There is also complex modulation of FoxO activity by
acetylation and deacetylation. FoxOs bind to coactivator
and corepressor complexes, such as CREB-binding
protein (CBP), p300/CBP-associated factor (PCAF), and
SIRT1 deacetylase, and subsequent acetylation or deace-
tylation affects their transcriptional activity (Brunet et al.,
2004; Frescas et al., 2005; Matsuzaki et al., 2005; van
der Horst et al., 2004; Vogt et al., 2005; Yang et al.,
2005). For example, acetylation of FoxO1 alters DNA bind-
ing activity and sensitivity to phosphorylation (Matsuzaki
et al., 2005), whereas Sirt1-mediated deacetylation of
FoxO1 appears to regulate subnuclear localization and
may impact selection of transcriptional programs (Frescas
et al., 2005) and has been reported to globally repress
FoxO1 transcriptional activity in the context of prostate
cancer cells (Yang et al., 2005).
Ubiquitination may also result in either activation or
inactivation of FoxO. Polyubiquitination targets FoxOs
for proteasomal degradation and requires phosphoryla-
tion of FoxOs by AKT, SGK, or IKKb and cytoplasmic
localization (Hu et al., 2004; Huang et al., 2005; Matsuzaki
et al., 2003; Plas and Thompson, 2003). Conversely,
oxidative stress can induce monoubiquitination of FoxOs
in the cytoplasm or nucleus and thereby mediate FoxO
activation (van der Horst et al., 2006).
Thus, unique combinations of phosphorylation, acetyla-
tion, and ubiquitination of FoxOs provide mechanisms to
‘‘fine tune’’ FoxO function (Vogt et al., 2005). Taken to-
gether, these posttranslational layers of control of FoxO
activity provide insight into the seeming paradox that
FoxOs can regulate both a protective response to stress-
ful stimuli as well as regulation of cell death, and mecha-
nistic explanations for FoxOs’ ability to orchestrate differ-
ent transcriptional programs depending on the nature of
the environmental stimulus.
Diverse Physiological Roles of FoxOs
In Vitro and In Vivo
Whereas FoxO inactivation by PI3K/AKT pathway favors
enhanced cell survival, cell proliferation, and stress sensi-
tivity, activation of FoxOs leads to apoptosis, cell-cycle
arrest, and stress resistance in most tissue contexts. In
the absence of growth factors or insulin, or in the presence
of stress stimuli, FoxO members reside in the nucleus
and are active as transcription factors (Figure 1). TheirCell Stem Cell 1, August 2007 ª2007 Elsevier Inc. 141
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include proapoptotic signaling via induction of TRAIL,
FasL, and Bim (Brunet et al., 1999; Dijkers et al., 2000;
Modur et al., 2002). In addition, FoxOs alter the expression
of a spectrumof genes that cumulatively result in cell-cycle
arrest. These include increased expression of p27, p130,
andp21and repressionofCyclinD expression that contrib-
utes to G1/S arrest (Kops et al., 2002b; Medema et al.,
2000; Seoane et al., 2004), activation of Cyclin G2 that
contributes to G0/G1 arrest (Martinez-Gac et al., 2004),
and activation of Cyclin B and Polo-like kinase associated
with G2/M arrest (Alvarez et al., 2001; Seoane et al., 2004).
Furthermore, the oxidative stress response is regulated
in part by FoxO induction of MnSOD and catalase (Kops
et al., 2002a; Nemoto and Finkel, 2002; Tran et al.,
2002). In concert with mediation of stress resistance,
FoxOs also facilitate DNA damage repair by upregulating
the expression of genes such as GADD45 and DDB1
(Ramaswamy et al., 2002; Tran et al., 2002). In differentiat-
ing cells, FoxOs can either promote or inhibit differentia-
tion, depending on the tissue context and FoxO isoform.
For example, expression of FoxO1 inhibits differentiation
of adipocytes and myoblasts (Hribal et al., 2003; Nakae
et al., 2003), whereas FoxO3 potentiates differentiation
of erythroid cells (Bakker et al., 2004). In addition, activa-
tion of FoxOs causes atrophy of fully differentiated skeletal
and cardiac muscle cells by decreasing protein synthesis
and cell size (Sandri et al., 2004; Stitt et al., 2004). Loss of
function of FoxOs in conditional knockout models as
a consequence of excision mediated by interferon-induc-
ible promoters also results in tumorigenesis, but in a highly
tissue dependent and selective manner (Paik et al., 2007).
Lastly, FoxOs are important regulators of glucose metab-
olism by upregulating the expression of genes involved in
gluconeogenesis (reviewed in Barthel et al., 2005). The
basis for the highly context-dependent effects of FoxO
gain or loss of function is not well understood. However,
there are several potential explanations for these differ-
ences that include varying levels of expression or redun-
dancy among different family members in different tissues
or unique environmental stresses encountered by various
tissue compartments. In addition, it is not clear why mam-
malian systems have four closely related FoxO family
members, whereasDrosophila or nematodes have a single
FoxO ortholog. However, it is tempting to speculate that
there is a degree of functional redundancy that reflects
the importance of these transcription factors in maintain-
ing integrity of mammalian systems and that there are
also distinctive and nonoverlapping functions that sub-
serve specific physiologic needs within a specific tissue
compartment.
Experimental support for functional redundancy comes
from loss-of-function studies in the murine system, in
which there may be minimal phenotypes associated with
loss of a single FoxO family member. For example,
FoxO4-deficient animals are viable and do not show any
overt phenotype (Hosaka et al., 2004), and FoxO3-defi-
cient animals are born with normalMendelian frequencies,
although females become infertile due to global primordial142 Cell Stem Cell 1, August 2007 ª2007 Elsevier Inc.follicle activation with subsequent oocyte exhaustion that
indicates a central role for FoxO3 in this germ cell com-
partment. FoxO3-deficient mice also exhibit defects in
glucose uptake and autoinflammation (Castrillon et al.,
2003; Lin et al., 2004). FoxO1 deficiency results in embry-
onic lethality at day E10.5 due to a defect in angiogenesis
(Furuyama et al., 2004; Hosaka et al., 2004), indicating
a nonredundant role for FoxO1 in vasculogenesis. The
phenotype of FoxO6-deficient animals is yet to be
reported, but its restricted expression pattern suggests
that it may play a role in embryologic development of the
central nervous system (Hoekman et al., 2006).
Evolutionary Conservation of FoxO Function
in Stress Resistance and Longevity
FoxO family members were first identified in C. elegans as
the ortholog DAF-16 (Kenyon et al., 1993). Loss of function
of DAF-16 reverts a longevity phenotype in nematodes
mutant in the DAF-2 insulin/IGF-1 receptor ortholog. Fur-
thermore, DAF-16 prolongs lifespan in part by induction of
the dauer phenotype, a developmentally arrested larval
stage that is observed during times of environmental
stress. DAF-16 mediates its effects on longevity by acti-
vating stress response genes, such as MnSOD (Honda
and Honda, 1999), as well as a number of other targets,
including cki-1, egl-10, and lin-2, among others (Baugh
and Sternberg, 2006; Oh et al., 2006), and this process
is mediated by a number of DAF-16 regulators, such as
SMK1 and kri-1 (Berdichevsky et al., 2006; Berman and
Kenyon, 2006; Lehtinen et al., 2006; Wolff et al., 2006).
Similarly, theDrosophila ortholog dFOXO acts as an effec-
tor of the PI3K/AKT pathway, and its activation results in
increased resistance to stress and enhanced longevity
(Giannakou et al., 2004; Hwangbo et al., 2004). Thus,
evolutionary and functional conservation of FoxO as an
effector of PI3K/AKT is indicative of the importance of
this group of transcription factors in maintaining and
regulating cellular homeostasis (Figure 2).
The Role of FoxOs in Regulating the Size
of the HSC Compartment
Recent data from several groups indicate that FoxOs play
essential regulatory roles in a number of physiologic
processes that influence hematopoietic stem cell number
and function. For example, young adult mice engineered
with conditional knockout alleles of FoxO1, FoxO3, and
FoxO4 and excised in the hematopoietic system with an
Mx-driven Cre recombinase show a marked reduction of
HSC (LT-LSK) numbers, which correlates with a functional
deficiency of long-term repopulation in both the competi-
tive and noncompetitive reconstitution assays (Tothova
et al., 2007). Furthermore, aged germline FoxO3 knockout
animals also show a reduction of the HSC pool and a
deficient repopulating capacity in secondary and tertiary
competitive transplantation assays (Miyamoto et al.,
2007). The relative subtlety of the HSC phenotype of
FoxO3 germline knockout animals, and the need for exci-
sion of all three FoxOs to fully manifest defects in apopto-
sis and cell-cycle aberrations, indicates that there is a
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Highly Conserved across Species
TheC. elegans,D.melanogaster, andmamma-
lian orthologs of FoxOs are highly conserved in
their ability to mediate stress resistance and
increase in lifespan as downstream effectors
of the PI3K/AKT pathway.significant degree of functional redundancy among the
different FoxO members.
FoxOs and HSC Quiescence
FoxOmembers play an important role at theG0-G1, G1-S,
and G2-M checkpoints by direct transcriptional modula-
tion of proteins that regulate these transitions. Loss of
FoxO1, FoxO3, and FoxO4 in the adult hematopoietic
system of animals results in a striking increase in the
proportion of HSCs (LSKs) in the active phases of cell
cycle (S/G2/M). This finding is restricted to the HSC
compartment and not present in the myeloid progenitor
compartment and correlates with an HSC-restricted mod-
ulation of FoxO target genes, including Rb/p130, Cyclin
G2, p27, p21, and Cyclin D2 (Tothova et al., 2007). Simi-
larly, germline loss of FoxO3 results in increased exit of
CD34LSKs, but not CD34+LSKs, into cycle and is
accompanied by decreased p27 and p57 expression.
Furthermore, germline loss of FoxO3 renders mice more
susceptible to cell-cycle-dependent myelotoxic agents
such as 5-FU (Miyamoto et al., 2007).
These effects of FoxOs on cell cycle and quiescence in
the HSC compartment can be understood in part from
studies of mouse models deficient in components of the
cell-cycle machinery, including direct targets of FoxO,
such as p21, p27, and D Cyclins. Mice deficient for
p21cip1/waf1 show increased numbers of HSCs and
increased HSC cycling, implicating p21 as a negative
regulator of HSC proliferation (Cheng et al., 2000b).
Similarly, p27kip1 is a negative regulator of progenitor
(Sca1+Lin+) proliferation in studies of p27-deficient mice
that show normal numbers and proliferation of HSCs but
increased number and proliferation of progenitors (Cheng
et al., 2000a). Embryos triply deficient for Cyclin D1, Cyclin
D2, and Cyclin D3 show reduced numbers of fetal liver
HSCs and progenitors and impaired proliferative ability
of both cell types, indicating a positive role of D Cyclins
in HSC proliferation (Kozar et al., 2004). Finally, p16 has
been recently shown to drive age-associated changes in
the HSC compartment, such as decreased self-renewal
and increased apoptosis with stress (Janzen et al.,
2006). These studies collectively indicate that proper
regulation of the cell-cycle machinery is essential for the
maintenance of the HSC and progenitor pools and provide
mechanistic insights into the effects of loss of function of
FoxOs on HSC cell-cycle abnormalities.The abnormalities in the HSC cell-cycle profile in the
context of FoxO deficiency are likely to have important
consequences on stem cell fate. The decrease in the G0
population and significantly reduced numbers of HSCs
in young conditional FoxO1/3/4 knockout animals or
aged FoxO3 knockout animals suggest that FoxO-defi-
cient stem cells may not be able to re-enter cell cycle
properly and are thereby deficient in their ability to self-
renew. In addition, there is a proportional increase in the
number of cycling cells, suggesting that some HSCs are
unable to exit the cell cycle in the absence of FoxOs and
thus accumulate in S/G2/M. FoxO-deficient HSCs are
therefore driven out of quiescence into cell cycle, resulting
in depletion of the stem cell pool.
FoxOs and Their Effects on HSC Survival
The role of apoptosis in HSC homeostasis has been tested
in H2K-BCL-2 transgenic mice engineered to overexpress
the antiapoptotic Bcl2 protein, a member of the Bcl2 fam-
ily of proteins, in all hematopoietic cells. These mice show
increased numbers of HSCs, accompanied by decreased
cycling and a competitive advantage in reconstitution as-
says. This observation underscores the importance of the
role that apoptosis plays in regulating and limiting stem
cell numbers (Domen et al., 2000), and as noted above,
FoxOs play an important role in regulation of this process.
Germline loss of FoxO3 resulted in no apparent changes in
apoptosis of hematopoietic stem and progenitor popula-
tions (Miyamoto et al., 2007); however, loss of FoxO1,
FoxO3, and FoxO4 in the adult hematopoietic system
results in significantly increased levels of apoptosis in
both HSC andmyeloid progenitor compartments (Tothova
et al., 2007). At face value, this finding is paradoxical,
because FoxOs are known to promote, rather than impair,
apoptosis. However, there is recent evidence from a
murine model of induced arthritis that FoxO3 deficiency
causes an increase in apoptosis that is correlated with
increased levels of FasL production (Jonsson et al.,
2005). It has therefore been suggested that FoxOs may
act as either a repressor or an activator of FasL produc-
tion, depending on the specific external stimulus and/or
tissue context. Thus, enhanced apoptosis and increased
exit out of quiescence due to FoxO deficiency may act in
concert to decrease the pool size of HSCs available for
self-renewal.Cell Stem Cell 1, August 2007 ª2007 Elsevier Inc. 143
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Proper HSC Function
Treatment of FoxO1/3/4-deficient animals with the antioxidant NAC restores levels of ROS, as well as proper functions in the HSC compartment, in-
cluding HSC number, cell cycling, and apoptosis, and implicates ROS as the causal agent in the FoxO-deficient HSC phenotype.FoxOs Mediate HSC Resistance to Physiologic
Oxidative Stress
Effect of Oxidative Stress on HSC Self-Renewal
Regulation of oxidative stress in the HSC compartment is
critical for the maintenance of HSC self-renewal. For
example, increased levels of reactive oxygen species
(ROS) impair HSC self-renewal in Atm-deficient mice via
a p38 MAPK-p16/p19-Rb-dependent mechanism (Ito
et al., 2004; Ito et al., 2006). In brief, Atm-deficient mice
develop early-onset bone marrow failure that correlates
with increased levels of ROS, activation of the p38
MAPK pathway, and increased expression of p16 and
p19 in the HSC compartment. Treatment of Atm-deficient
animals with antioxidant N-acetyl-L-cysteine (NAC), as
well as a p38 MAPK-specific inhibitor, rescues these
mice from bone marrow failure. In addition, changes
similar to those observed in Atm-deficient mice were
also present in HSCs isolated from mice that were treated
with the oxidant buthionine sulfoximine (BSO), aswell as in
HSCs that underwent multiple rounds of serial transplan-
tation (Ito et al., 2006). Collectively, analysis of the Atm-
deficient HSCs shows that maintenance of the proper
oxidative environment is essential for normal HSC func-
tion, although the exact mechanisms of ATM deficiency-
induced increase in ROS and subsequent p38 MAPK
activation remain to be elucidated.
FoxOs Affect HSC Integrity by Regulating ROS
FoxO family members protect quiescent cells from oxida-
tive stress by upregulation of genes involved in their
detoxification, such as MnSOD, catalase, and GADD45.
HSCs (LSKs), but not myeloid progenitor cells isolated
from FoxO1/3/4 conditional knockout animals, show
increased ROS, which correlates with enrichment of
genes that regulate ROS in wild-type versus FoxO-
deficient HSCs (Tothova et al., 2007). Similarly, germline
loss of FoxO3 results in increased levels of ROS in the HSC
(LSK) compartment and correlates with decreased level of
SOD2 and catalase expression and increased activation of
p38 MAPK in CD34LSK cells (Miyamoto et al., 2007).
As observed in Atm-deficient mice, the HSC defect in
FoxO-deficient mice is reverted with the antioxidant NAC
(Figure 3). NAC treatment of the triple FoxO conditional144 Cell Stem Cell 1, August 2007 ª2007 Elsevier Inc.knockout mice restores the size of the HSC compartment,
and the rescue of the HSC compartment size correlates
with reversion of the cell cycle and apoptosis defects, as
well as the hematopoietic colony forming unit ability,
long-term cobblestone area forming ability, short-term
repopulating ability in vivo, and restoration of a FoxO tran-
scriptional program (Tothova et al., 2007).
Treatment of FoxO3 germline knockout animals with
NAC reveals a partial inhibition of p38 MAPK activation
in CD34LSK cells, and treatment with the p38 MAPK
inhibitor rescues the defect in LTC-IC formation (Miya-
moto et al., 2007). These experiments collectively imply
that ROS accumulation and p38 MAPK activation impair
HSC function in FoxO-deficient animals.
Regulation of ROS during Hematopoietic
Development
The HSC-specific increase in levels of ROS that are caus-
ally implicated in the FoxO-deficient stem cell phenotype
is also accompanied by a marked increase in ROS levels
with the transition from HSCs to myeloid progenitors
that is unaffected by FoxO deficiency. This observation
suggests that there might be a FoxO-independent devel-
opmental program that regulates ROS levels in myeloid
progenitors. Gene set enrichment analysis (GSEA) of
HSCs and myeloid progenitors of FoxO1/3/4 conditional
knockout animals supports the existence of a develop-
mentally regulated program that is engaged with the
transition from HSCs to myeloid progenitors. Of note,
FoxO-deficient and wild-type myeloid progenitors show
enrichment for the same subset of ROS genes, and this
gene set is different from that observed in the HSC com-
partment. These data suggest that there is a subset of
ROS genes that is regulated by FoxOs in the HSC com-
partment and serves to decrease levels of ROS and,
with this, their deleterious effects on HSC survival and
function. In the context of HSCs, the 10-fold increase
in ROS results in a striking decrease in the longevity of
these cells that are normally capable of self-renewal
over the lifetime of the organism in which they reside.
However, with the transition of HSCs to myeloid progeni-
tors, GSEA identifies a developmentally regulated tran-
scriptional program that is FoxO independent and that is
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et al., 2007).
It is perhaps not surprising that ROS levelswould be dra-
matically elevated with this developmental transition of
HSCs to myeloid progenitors. A spectrum of terminally dif-
ferentiated myeloid lineage cells, including neutrophils,
monocytes, eosinophils, and mast cells, are a first line of
host defense to infectious agents, such as bacteria. These
cells employ a variety of strategies to kill their prey, includ-
ing ROS. Thus, HSCs and myeloid progenitors have
opposing relationships to ROS. HSCs must be protected
from the effect of ROS to maintain quiescence, self-
renewal, and longevity. In contrast, commitment by the
HSC compartment toward myeloid differentiation requires
marked upregulation of ROS to subserve the role of termi-
nally differentiated myeloid lineage cells as professional
generators of ROS with bactericidal intent. Current experi-
mental evidence supports the notion that this dichotomous
relationship to ROS between these intimately related
hematopoieticcompartments is regulated, perhapsnotun-
expectedly, by two different transcriptional programs. The
ROS protective program in HSCs is enacted by FoxO tran-
scription factors that are highly redundant in this role,
whereas an ROS generating program is engaged by an
Figure 4. FoxO Regulation of ROS during Hematopoietic
Development and Its Proposed Effects on Fate Determination
and Longevity
FoxO transcription factors may contribute to fate determination by
providing compartmentalization of antioxidant enzymes. Under normal
hematopoietic homeostasis, HSCs are some of the longest-lived cells
as a result of their ability to maintain low levels of ROS. Decreased
FoxO activity correlates with decreased FoxO-dependent antioxidant
expression and increased ROS levels, which may act as the required
signal directing the transition from HSCs to more mature fates. Loss
of FoxOs results in a significant increase in ROS in the HSC compart-
ment with a subsequent decrease in lifespan of these cells. (Artwork
courtesy of Eric Smith.)as yet unknown, FoxO-independent mechanism to facili-
tate normal terminal differentiation of myeloid cells (To-
thova et al., 2007). It will be of considerable interest to
gain mechanistic insights into this transition.
It is also of interest that increased ROS dramatically
shortens the lifetime of HSCs, yet myeloid progenitors
have 10-fold higher levels of ROS than FoxO-deficient
HSCs. It seems likely that there are mechanisms that
serve to protect myeloid progenitors from ROS exposure
during development. Nonetheless, terminally differenti-
ated myeloid cells are among the shortest-lived cells in
mammals. It is tempting to speculate that they must gen-
erate high levels of ROS for their normal function but have
an ephemeral existence as a consequence.
FoxOs are expressed with the transition from HSCs to
myeloid progenitors, which raises the question of how
ROS levels can override the inherent activity of FoxOs in
repressing levels of ROS. Myeloid progenitors differenti-
ate under the influence of a spectrum of exogenous cyto-
kines, thus it is possible that there is an inherently higher
level of activation of the PI3K/AKT pathway in this com-
partment compared with HSCs, with resultant inactivation
of FoxO. Indeed, wild-type CD34LSKs show greater ac-
cumulation of nuclear FoxO3 than CD34+LSKs, which
have increased levels of Akt activation and lipid raft forma-
tion (Yamazaki et al., 2006). Even with negation of the
countervailing influence of FoxOs on ROS, the observa-
tion that increased ROS in myeloid progenitors is not de-
pendent on FoxOs strongly supports the hypothesis that
there is a developmentally regulated program that
increases ROS in myeloid progenitors.
The deleterious effects of high levels of ROS are well
known—indeed these are in part responsible for cytocidal
activity in terminally differentiated myeloid cells. However,
there is evidence that certain ROS, such as hydrogen
peroxide (H2O2), can not only act as oxidative stressors,
causing cellular damage, but also as important and highly
selective signalingmolecules that regulate a variety of bio-
logical functions (reviewed in Veal et al., 2007). Building on
the premise that ROS can act as signaling molecules, and
theobservation that levels ofROSare significantly higher in
myeloid progenitors than HSCs, it could be speculated
that increased levels of ROS act as the required intracellu-
lar signal directing the transition from HSCs to myeloid
progenitor fates by triggering exit out of quiescence and
skewing the balance away fromself-renewal toward differ-
entiation (Figure 4). In vivo, this transition could be enabled
by FoxO-driven compartmentalization of antioxidant ex-
pression within the relatively hypoxic bone marrow niche,
and/or modulation of oxidizing proteins with catalytic site
cysteines that are exquisitely sensitive to redox potential
or hypoxia-inducible factor (HIF) expression.
Linking the Role of FoxOs in HSCs to Other
Components of the PI3K/AKT Pathway
The essential role of the PI3K/AKT pathway in hematopoi-
etic homeostasis and maintenance of HSC integrity is
supported by recent reports of hematopoietic defects in
mice with conditional loss of PTEN in the hematopoieticCell Stem Cell 1, August 2007 ª2007 Elsevier Inc. 145
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a dual specificity lipid and protein phosphatase that con-
verts PtdIns(3,4,5)P3 to PtdIns(3,4,5)P2 and antagonizes
PI3K/AKT activity. Deletion of PTEN results in hyperactiva-
tion of the PI3K/AKT pathway, and activation or
inactivation of its multiple downstream targets, including
GSK3b, FoxO, mTOR, IKK, Bad, p27, and ASK1. Mice
deficient for Pten in the hematopoietic system show
reduction in the number of HSCs and developmyeloprolif-
erative disease that rapidly evolves to acute leukemia
(Yilmaz et al., 2006; Zhang et al., 2006).
Pten-deficient mice havemany phenotypic similarities to
FoxO-deficient mice. There are similar perturbations of
the myeloid and lymphoid compartments, associated with
development of a myeloproliferative phenotype and T cell
lymphomas, although FoxO-deficient mice do not develop
acute leukemia. Perhaps the most striking similarity, how-
ever, is the HSC phenotype in the two models. Deficiency
of Pten or FoxO results in enhanced cycling of HSCs and
impaired multilineage reconstitution, with consequent de-
pletion of the stem cell pool. In FoxO-deficient mice, the
HSCphenotype ismechanistically linked to increased levels
of ROS. However, it is not known to what extent ROS con-
tributes to the HSC phenotype in Pten-deficient mice.
Pten inactivation results in AKT activation, and acti-
vated AKT phosphorylates and inactivates FoxO. Thus,
one possible explanation for the similarity of the Pten-
and FoxO-deficient HSC phenotypes is that the Pten de-
ficiency is attributable to loss of function of FoxOs in this
context. However, treatment of Pten-deficient animals
with rapamycin, a specific inhibitor of mTOR, restores
normal HSC function. This finding taken at face value
would suggest that mTOR activation in Pten-deficient
mice is the primary basis for the observed HSC pheno-
type. These data are also puzzling in light of literature
suggesting that rapamycin inhibition of mTOR signaling
results in feedback activation of AKT that would be pre-
dicted to inactivate FoxO function (Harrington et al.,
2004). These data thus present another interesting
paradox that might be explained by off-target effects of
rapamycin or by as yet unidentified pathways activated
by mTOR that influence FoxO function.
mTOR (mammalian target of rapamycin) is a serine/thre-
onine kinase that acts as the catalytic subunit of two struc-
turally and functionally distinct complexes: mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2)
(reviewed in Bhaskar and Hay, 2007). mTORC1 contains
the core componentsmTORandmLST8/GbL in a complex
with raptor, regulates ribosomal biogenesis and protein
synthesis, and is negatively regulated by the TSC1/TSC2
(tuberous sclerosis) complex. AKT activates mTORC1 in
part by direct phosphorylation and by phosphorylation
and inactivation of TSC1/TSC2. mTORC2 has the same
core components complexed with rictor and SIN1, but in
contrast, mTORC2 activates AKT by phosphorylation of
residue Ser473. The mechanism(s) of regulation of
mTORC2 activity is not well understood, although insulin
and growth factor stimulation have been shown to result
in mTORC2 activation.146 Cell Stem Cell 1, August 2007 ª2007 Elsevier Inc.An attractive explanation that unites the phenotypes of
FoxO- and Pten-deficient HSCs derives from a recent
report (Sarbassov et al., 2006) demonstrating a previously
unrecognized mechanism of action of rapamycin. Rapa-
mycin, in addition to inhibition of the mTORC1 complex,
may also inhibit the assembly and subsequently the func-
tion of the mTORC2 complex in a tissue-specific manner,
including hematopoietic cells. In contrast to inhibition of
mTORC1 that results in feedback activation of AKT, inhibi-
tion of mTORC2 results in loss of phosphorylation and
inactivation of AKT and is correlated with increased
FoxO activity. Genetic strategies that result in loss of func-
tion of the mTORC2 complex provide further support for
this observation. For example, genetic deletion of the
rictor component of mTORC2 results in hemiphosphoryla-
tion of AKT in which Ser473 is not phosphorylated.
Hemiphosphorylated AKT lacks the ability to phosphory-
late and thereby inactivate FoxO, but there is no apparent
effect on other AKT targets (Guertin et al., 2006). These
data provide further evidence that functional mTORC2
complex is essential for AKT-mediated inactivation of
FoxO. In addition, these findings are in consonance with
the observation that inactivation of the mTORC2 by
prolonged rapamycin treatment results in a context-
dependent reactivation of FoxO, including hematopoietic
and AML cell lines (Sarbassov et al., 2006; Zeng et al.,
2007). Therefore, it is possible that restoration of the
Pten-deficient HSC phenotype with rapamycin may be
attributed to reactivation of FoxO, and this hypothesis
warrants further investigation.
Role of FoxOs in Other Embryonic and Somatic
Stem Cell Compartments
It is of interest to relate the effects of FoxO deficiency in
the hematopoietic system to other tissue contexts. Stud-
ies of FoxO3 germline knockout animals have shown
that isolated FoxO3 deficiency results in oocyte exhaus-
tion and infertility due to global activation of the primordial
ovarian follicle (Castrillon et al., 2003). These phenotypic
attributes in germ cells are similar to those observed in
HSCs and suggest that FoxOs may play an important
role in the maintenance and integrity of stem cell compart-
ments in a broad spectrum of tissues. Studies of the role of
FoxOs in the maintenance of other tissue stem cell com-
partments will be facilitated by the availability of the triple
FoxO conditional knockout mouse model that can be
crossed to different tissue-specific Cre recombinase
mouse strains. In addition, the similarities between the
role of FoxOs in regulation of quiescence and longevity
of HSCs in vertebrates, and regulation of dauer diapause
and life span determination in C. elegans by the FoxO
ortholog DAF-16, further highlight the evolutionarily
conserved role of FoxOs in regulation of longevity.
FoxO and Cancer
FoxOs as Tumor Suppressors
FoxO inactivation is a frequent event in cancer develop-
ment. Constitutive activation of the PI3K/AKT pathway
with concomitant inactivation of FoxO is a hallmark of
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glioblastoma and prostate cancer (reviewed in Altomare
and Testa, 2005). FoxOs are thus attractive candidates
as tumor suppressors in this context, given their role in
regulation of cell-cycle arrest, apoptosis, DNA repair,
and stress resistance.
FoxO transcription factors were initially identified in
humans by virtue of their involvement in chromosomal
translocation breakpoints in human tumors. These include
t(2;13)(q35;q14) or t(1;13)(p36;q14) that result in expres-
sion of a Pax3-FoxO1 or Pax7-FoxO1 fusion gene,
respectively, in alveolar rhabdomyosarcoma (Anderson
et al., 1998; Davis et al., 1994; Galili et al., 1993). In addi-
tion, acute myeloid leukemias (AMLs) are associated with
t(6;11)(q21;q23) or t(X;11)(q13;q23) that result in expres-
sion of MLL-FoxO3 and MLL-FoxO4 fusion genes,
respectively (Borkhardt et al., 1997; Hillion et al., 1997;
Parry et al., 1994).
A more general role of FoxOs in tumorigenicity stems
from their function as negative regulators of cell prolifera-
tion and cell survival. Thus, inactivation of FoxOs, either by
means of nuclear exclusion or posttranslational modifica-
tions, is a frequent event in multiple cancers, such as
breast or prostate cancer (Hu et al., 2004; Modur et al.,
2002). Moreover, FoxOs are thought to interact with
a number of tumor suppressors and oncogenes, such as
p53, SMAD, and b-catenin (Essers et al., 2005; Nemoto
et al., 2004; Seoane et al., 2004; You and Mak, 2005). De-
spite these data providing strong support for a role for loss
of function of FoxO family members in cancer, analysis of
single FoxO knockout models has identified a subtle can-
cer proclivity only in FoxO3 germline knockout animals
(Paik et al., 2007).
Recent development of amousemodel engineered with
conditional knockout alleles of FoxO1, FoxO3, and FoxO4
provides direct evidence that FoxO transcription factors
are bona fide, functionally redundant tumor suppressors
in that the loss of these FoxO family members results in
development of thymic lymphomas and widespread
hemangiomas (Paik et al., 2007). The tumor spectrum ob-
served in these mice is of a narrower range than might
have been anticipated based on widespread expression
and physiologic importance of FoxOs in various tissues.
This may be due in part to the observation that use of
Mx-Cre restricts excision to certain tissue compartments,
and it will be of interest to assess loss of FoxO function on
tumorigenesis in other contexts. Nonetheless, excision
was documented in a number of tissues in this model sys-
tem in which tumors did not develop, indicating that there
is context-dependent tumor suppression mediated by
FoxO (Paik et al., 2007).
FoxOs and Malignant Stem Cells
Cancer is a disorder of self-renewal, and yet the stem cell
defects in FoxO-deficient HSCs are somewhat at odds
with the documented role of FoxOs as a tumor suppres-
sor. However, in both the myeloproliferative phenotype
and in the T cell lymphoma of FoxO1/3/4 knockout ani-
mals, the available evidence suggests that self-renewal
is restored to the FoxO-deficient cells that would beexpected to lack such potential. For example, the T cell
lymphoma is readily transplantable to secondary recipi-
ents and in both the T cell and myeloproliferative pheno-
types there is complete excision of all three FoxO alleles
(Paik et al., 2007; Tothova et al., 2007). The apparent res-
toration of self-renewal potential in the context of FoxO
deficiency is likely related to the acquisition of secondary
mutations. Although the mechanism for potentiation of
second mutations is not known, it is possible that oxida-
tive damage in the absence of FoxOs is a contributing
factor.
Many cancers, including leukemia, seem to depend on
a small population of cancer stem cells for their continued
growth and propagation (reviewed in Huntly and Gilliland,
2004). The existence of leukemia stem cells (LSCs) was
first demonstrated in the context of acute myeloid leuke-
mias by Dick and colleagues (Bonnet and Dick, 1997).
LSCs comprise only a small fraction of leukemia cells
that have limitless self-renewal capacity and provide
long-term growth potential of the tumor. In light of the
cancer stem cell theory, it is possible that the second hit
mutations in FoxO-deficient micemay serve a role to com-
pensate for the self-renewal defects that are present in the
HSC compartment as a result of FoxO loss. This could be
accomplished by mutations that result in restoration of
normal levels of ROS in the leukemic stem cell compart-
ment and/or activation of physiologic mechanisms that
render leukemic stem cells less susceptible to oxidative
damage. Examples could include mutations that result in
increased expression of ROS scavenging enzymes or
those that result in downregulation of p16 that would be
predicted to dissociate the detrimental effects of ROS
on self-renewal of the HSC compartment.
The finding that FoxOs play a key role in the mainte-
nance of normal ROS levels in HSCs could have significant
therapeutic implications in the realm of malignant hemato-
poiesis. Observations in the context of normal hematopoi-
etic stem cells suggest the possibility that the self-renewal
potential of leukemic stem cells might be sensitive to high
levels of reactive oxygen. If so, this liability may be an
Achilles heel for a cancer stem cell and might be exploited
therapeutically (Huang et al., 2000). Indeed, there is evi-
dence suggesting that treatment of human AML stem
and progenitor cells with parthenolide, a naturally occur-
ring molecule that can induce ROS, preferentially targets
AML cells and induces robust apoptosis (Guzman et al.,
2005). Most, if not all, myeloid leukemias, and indeed
most solid tumors, are characterized by constitutive acti-
vation of the PI3K/AKT pathway with resultant FoxO defi-
ciency. Based on recent findings related to FoxO-deficient
and normal HSCs, it is tempting to speculate that leukemia
stem cells—or other cancer stem cells—exert significant
cellular homeostatic mechanisms to manage the obligate
increase in ROS associated with loss of function of FoxO
family members. It is thus plausible that oxidative agents
that would have minimal effects on normal hematopoietic
constituents might be lethal for leukemia stem cells that
must manage the increase in ROS that is associated
with constitutive activation of the PI3K/AKT/FoxO axisCell Stem Cell 1, August 2007 ª2007 Elsevier Inc. 147
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ReviewFigure 5. FoxOs in Normal versus
Malignant HSCs
Genetic loss of FoxOs in the HSC compart-
ment results in increased levels of ROS and
loss of self-renewal of HSCs. Most, if not all,
myeloid leukemias, including those mediated
by BCR/ABL, are characterized by constitutive
activation of the PI3K/AKT pathway with resul-
tant posttranslational FoxO inactivation. It re-
mains to be determined whether leukemic
stem cells have increased levels of ROS and
what mechanisms render their unlimited self-
renewal potential in spite of predicted high
levels of ROS.(Figure 5). This concept is now emergingwithin other path-
ways, such as the RAS-RAF-MEK pathway as well, where
tumor cells harboring activating mutations in the RAS-
RAF-MEK pathway can be selectively killed with ligands
binding directly tomitochondrial voltage-dependent anion
channels (Yagoda et al., 2007).
It is also interesting to speculate that agents that directly
or indirectly inhibit the PI3K/AKT pathway in cancer might
paradoxically protect the leukemic stem cell population.
For example, imatinib treatment of BCR-ABL-positive
CML may result in molecular remission but does not
cure the disease due to lack of eradication of a quiescent
BCR-ABL-positive stem cell population. It is possible that,
in the leukemia stem cell compartment, inhibition of PI3K/
AKT signaling by inhibiting BCR-ABL activity would result
in reactivation of FoxOs and induction of quiescence and
stress resistance in the leukemia stem cell population.148 Cell Stem Cell 1, August 2007 ª2007 Elsevier Inc.This could potentially explain the persistence of this
population of cells in the presence of therapeutic and
pharmacologically active concentrations of imatinib.
Therapeutic Targeting of FoxOs in Regenerative
and Cancer Medicine
FoxOs are key regulators of HSC integrity, and depletion
of the HSC compartment upon loss of FoxOs shares cer-
tain phenotypic attributes of aging. These observations
suggest the intriguing possibility that therapeutic activa-
tion of FoxOs could result in lifespan prolongation of
HSC or other tissue stem cells, which in turn could be ben-
eficial in the context of bone marrow transplantation or
bone marrow failure syndromes. There are several poten-
tial ways by which FoxOs could be targeted for activation.
These strategies might include development of specific
inhibitors of mTORC2 complex formation or function,Figure 6. Proposed Model of FoxO
Function in the Maintenance of the
Integrity of HSC Compartment
FoxOs maintain quiescence, enhance survival,
and mediate resistance to physiologic oxida-
tive stress and thereby maintain self-renewal
of the HSC compartment. (All of the target
genes in bold have been directly investigated
in studies of FoxOs in HSCs to date, all of the
target genes in regular font have been linked
to FoxO function in previous studies, and all
of the target genes with a question mark
remain to be investigated as downstream
targets of FoxOs that contribute to the mainte-
nance of HSC self-renewal.)
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the nucleus (Kau et al., 2003), or agents affecting the
phosphorylation, acetylation, and ubiquitination status of
these proteins.
More selective inhibition of the PI3K/AKT pathway
targeting FoxO reactivation could potentially be accom-
plished by use of selective inhibitors of Akt phosphoryla-
tion on Ser473. Recent data demonstrated that mouse
embryo fibroblasts (MEFs) derived from rictor null mice
that lack a functional mTORC2 complex do not phosphor-
ylate AKT on Ser473, and the sole functional consequence
of rictor deficiency in the context of PI3K/AKT signaling is
the inability of hemiphosphorylated AKT to phosphorylate
and inactivate FoxO (Guertin et al., 2006). Therefore, inhib-
itors specifically targeting the mTORC2 complex could be
of potential clinical use by enabling selective reactivation
of FoxO.
Putting It All Together: A Model of FoxO Function
in the HSC Compartment
FoxO transcription factors play a critical role in hemato-
poietic homeostasis by regulating the HSC compartment.
Experimental evidence thus far suggests that, under
homeostatic conditions, FoxO transcription factors main-
tain self-renewal of hematopoietic stem cells, and is
consistent with the hypothesis that FoxOs cooperate to
affect quiescence of HSCs by regulation of mediators of
the G0-G1 and G1-S arrest in this compartment, including
Rb/p130, Cyclin G2, p27, p57, p21, and Cyclin D2, and
prevent aberrant entry into cycle. Second, FoxOs collec-
tively act to inhibit apoptosis in the HSC compartment
and therefore contribute to the maintenance of the stem
cell pool size. Third, current evidence is consistent with
a critical role of FoxOs in mediating resistance to physio-
logic oxidative stress in the HSC compartment through
known downstream targets of FoxO, including MnSOD,
catalase,ATM, and p16, and thereby potentiate properties
of self-renewal. A proposed model includes a positive
feedback loop between ROS and FoxO activation,
because it has been well established that phosphorylation
of FoxOs by JNK or deacetylation of FoxOs by SIRT1
results in nuclear localization and activation of FoxO. Fur-
thermore, increased levels of ROS result in activation of
p38 MAPK, at least in the context of FoxO3 germline defi-
ciency, with a subsequent increase in p16 expression,
which may inhibit self-renewal by downregulation of Hes
1. Finally, oxidative stress-enhanced binding of FoxOs to
b-catenin may counteract the deleterious actions of ROS
on HSC self-renewal. A speculative but attractive hypoth-
esis is that FoxOs could also potentiate b-catenin’s ability
to engage self-renewal programs (Figure 6).
Thus, studies of FoxOs inmammals have several impor-
tant implications. They suggest a central role for manage-
ment of reactive oxygen in hematopoietic stem cell
homeostasis. These studies further present the interesting
conundrum of the requirement for low ROS for HSC integ-
rity but an absolute requirement for a marked increase in
ROS during hematopoietic development. Furthermore,
these studies suggest a role for targeting ROS in treatmentof cancer and suggest that FoxOsmaybeuseful targets for
enhancing stem cell longevity and perhaps in tissue
regeneration. Thus, cumulatively, analysis of FoxO
function across species has informed not only our under-
standing of stem cell function and integrity but also has
suggested important potential therapeutic applications.
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